eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Novartis Consumer Health

Novartis Consumer Health UK Ltd, Park View, Riverside Way, Watchmoor Park, Camberley, Surrey, GU15 3YL, UK
Telephone: +44 (0)1276 687300
Fax: +44 (0)1276 687284
Medical Information Direct Line: +44 (0)1403 323 046
Medical Information e-mail: medicalaffairs.uk@novartis.com
Customer Care direct line: +44 (0)1276 687290
Medical Information Fax: +44 (0)1403 324 024

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 13/12/2010
SPC Nicotinell Mint 1mg Lozenge

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 13/12/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 1 -Name of the Medicinal product
  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on Ability to Drive and Use Machines
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 5.2 - Pharmacokinetic Properties
  • Change to section 5.3 - Preclinical Safety Data
  • Change to section 6. 4 - Special Precautions for Storage
  • Change to section 9 - Date of first Authorisation/renewal of the Authorisation
  • Change to section 10 date of revision of the text
Date of revision of text on the SPC:   19-Nov-2010
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Section 1

Addition of word ‘compressed’.

 

Section 2

Addition of Excipients(s): aspartame (0.01 g), maltitol (0.9 g) and sodium (9.8 mg).

For a full list of excipients, see section 6.1

 

Section 4.1

Paragraph 1: Deletion of words ‘Nicotinell treatment is indicated for the .....’

 

Paragraph 2: Patient counselling and support...’ replaces ‘advice and support...’

 

Section 4.2

Adults & Elderly

Paragraph 2: Words changed from: ‘...medium nicotine dependency’ to ‘..low to moderate nicotine dependency’.

 

Paragraph 3: Addition of words: ‘or very strong’ after ‘strong’ and ‘nicotine dependency’.

Paragraph 5: Clarification of high dose form as 2mg lozenge and low dose form as 1mg lozenges.

 

New paragraph added:

Patients who have been using oral nicotine replacement therapy beyond 9 months are advised to seek additional help and information from health care professionals.

 

Paragraph regarding use of acidic beverages has been moved from Children and adolescents (<18 years) section to section called Directions for use.

 

Deletion of paragraph:  Nicotinell Mint 1 mg lozenge is sugar-free.

 

Section 4.3

Change of wording from ‘Hypersensitivity to any excipients of the lozenge’ to ‘Hypersensitivity to nicotine or to any of the excipients’.

 

Section 4.4

New Heading added:  Special warnings about excipients and related warnings grouped underneath.

 

Paragraph added:

Nicotinell lozenges contain sweeteners, including aspartame and maltitol.

 

Addition of words ‘a source of frustose’ added after ...’contains aspartame (E951)...’

 

Section 4.5

‘olanzapine’ moved from list in paragraph 3 to list in paragraph 2.

 

Paragraph 4: Deletion of word ‘reduction’ between words ‘heart rate’ and ‘and reduced’.

 

Section 4.7

Wording added: ‘one should take into consideration that’ between ‘nevertheless’ and ‘smoking cessation’

 

Section 4.8

Paragraph 1: Addition of: ‘Non dose-dependent adverse reactions are as follows: hypersensitivity, angioneurotic oedema and anaphylactic reactions.’

 

Paragraph 3: Last sentence changed from :

‘Those with a tendency to indigestion may suffer initially from slight dyspepsia or heartburn.’ to ‘Those who are prone to indigestion may suffer initially from minor degrees of dyspepsia or heartburn; slower sucking will usually overcome this problem.‘

 

Addition of paragraph: ‘Increased frequency of aphthous ulcer may occur after abstinence from smoking.’

 

New paragraph: Adverse reactions are listed below, by system organ class and frequency.  Frequencies are defined as : very common (≥1/10), common (≥1/100) to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000, <1/1,000) or very rare (<1/10,000).

 

Addition of :  Immune system disorders:  Rare: hypersensitivity, angioneurotic oedema and anaphylactic reactions.

 

Section 4.9

Treatment of overdose:

‘Treatment of overdose should be immediate as symptoms may develop rapidly. Emesis is usually spontaneous. Administration of oral activated charcoal and gastric lavage should be considered as soon as possible and within 1 hour of ingestion. Monitor vital signs and treat symptomatically.’

 

Replaces :

‘In the event of overdosage, vomiting should be induced with syrup of ipecac or gastric lavage carried out (wide bore tube). A suspension of activated charcoal should then be passed through the tube and left in the stomach. Artificial respiration with oxygen should be instituted if needed and continued for as long as necessary. Other therapy, including treatment of shock, is purely symptomatic.’

 

Section 5.2

 

Paragraph 3: (2-)3 1/kg has changed to 2-3 1/kg.

Paragraph 4:   The words’..concomitant drugs...’ has been replaced with ‘...concomitant medicinal products..’.

 

Section 5.3

Paragraph 1:

Nicotine was positive in some in-vitro genotoxicity tests but there are also negative results with the same test systems. Replaces : No definite conclusion can be drawn on the genotoxic activity of nicotine in vitro.

 

Section 6.4

Deletion of words ‘Store in the original package’.

 

Section 9

Date of first authorisation: 20 July 1999. Date of last renewal:16 December 2008

Replaces : 20 July 1999

 

 

Section 10

Date changed from 10 January 2008 to 19 November 2010

Updated on 31/03/2008 and displayed until 13/12/2010
Reasons for adding or updating:
  • Change to section 6. 5 - Nature and Contents of Container
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   01/2008
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Section 5.3 Preclinical safety data - correction of spelling error
Section 6.5 Nature and contents of container - Addition of pack sizes 72 and 144
Updated on 28/09/2007 and displayed until 31/03/2008
Reasons for adding or updating:
  • Change to separate SPCs covering individual presentations
Date of revision of text on the SPC:   11/2004
Legal Category:   GSL
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company

Change from a combination 1 and 2 mg SPC to individual strength SPCs
Updated on 30/09/2003 and displayed until 28/09/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 30/09/2003 and displayed until 30/09/2003
Reasons for adding or updating:
  • New SPC for new product

Active Ingredients/Generics

 
   nicotine bitartrate dihydrate